Surgical Endoscopy

, Volume 21, Issue 7, pp 1184–1189 | Cite as

Health economic evaluation of therapeutic strategies in patients with idiopathic achalasia: results of a randomized trial comparing pneumatic dilatation with laparoscopic cardiomyotomy

  • S. Kostic
  • E. Johnsson
  • A. Kjellin
  • M. Ruth
  • H. Lönroth
  • M. Andersson
  • L. Lundell



We have prospectively collected information concerning the costs incurred during the management of patients allocated to either forceful dilatation or to an immediate laparoscopic operation because of newly diagnosed achalasia.


Fifty-one patients with newly diagnosed achalasia were randomized to either pneumatic dilatation to a diameter of 30–40 mm or to a laparoscopic myotomy to which was added a posterior partial fundoplication. Follow-ups were scheduled at 1, 3, 6, and 12 months after inclusion. At each follow-up visit a study nurse interviewed the patients regarding symptoms and their quality of life (QoL) and a health economic questionnaire was completed. In the latter questionnaire, patients were asked to report the presence and character of contacts with the healthcare system since the last visit.


In the dilatation group six patients (23%), including the patient who was operated on because of perforation, were classified as failures during the first 12 months of follow-up compared to one (4%) in the myotomy group (p = 0.047). Five of those classified as failures in the dilatation group subsequently had a surgical myotomy and the sixth patient was treated with repeated dilatations. The patient classified as failure in the myotomy group was treated with endoscopic dilatation. The initial treatment cost and the total costs were significantly higher for laparoscopic myotomy compared to a pneumatic dilatation-based strategy (p = 0.0002 and p = 0.0019, respectively) When the total costs were subdivided into the different resources used, we found that the single largest cost item for pneumatic dilatation was that for hospital stay and that for laparoscopic myotomy was the actual operative treatment (operating room time) The cost-effectiveness analysis, relating to the actual treatment failures, revealed that the cost to avoid one treatment failure (incremental cost-effectiveness ratio) amounted to €9239.


The current prospective, controlled clinical trial shows that despite a higher level of clinical efficacy of laparoscopic myotomy to prevent treatment failure in newly diagnosed achalasia, the cost effectiveness of pneumatic dilatation is superior, at least when a reasonable time horizon is applied.


Achalasia Balloon dilatation Myotomy Symptoms Treatment failure Health economic evaluation Laparoscopy 


  1. 1.
    Sonnenberg A, Massey BT, McCarty DJ, Jacobsen SJ (1993) Epidemiology of hospitalisation for achalasia in the United States. Dig Dis Sci 38:233–244PubMedCrossRefGoogle Scholar
  2. 2.
    Mayberry JF, Atkinson M (1987) Variations in the prevalence of achalasia in Great Britain and Ireland: an epidemiological study based on hospital admissions. Q J Med 62:67–74PubMedGoogle Scholar
  3. 3.
    Howard PJ, Maher L, Pryde A, Cameron EW, Heading RC (1992) Five years prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut 33:1011–1015PubMedGoogle Scholar
  4. 4.
    Ben-Meir A, Urbach DR, Khajanchee YS, Hansen PD, Swanstrom LL (2001) Quality of life before and after laparoscopic Heller myotomy for achalasia. Am J Surg 181:471–474PubMedCrossRefGoogle Scholar
  5. 5.
    Urbach DR, Tomlinson GA, Harnish JL, Martino R, Diamant NE (2005) A measure of disease-specific health related quality of life for achalasia. Am J Gastroenterol 100:1668–1676PubMedCrossRefGoogle Scholar
  6. 6.
    Spiess AE, Kahrilas PJ (1998) Treating achalasia: from whalebone to laparoscope. JAMA 280:638–642PubMedCrossRefGoogle Scholar
  7. 7.
    Abir F, Modlin I, Kidd M, Bell R (2004) Surgical treatment of achalasia: current status and controversies. Dig Surg 21:165–176PubMedCrossRefGoogle Scholar
  8. 8.
    Vantrappen G, Hellemans J, Deloof W, Valembois P, Vandenbroucke J (1971) Treatment of achalasia with pneumatic dilatations. Gut 121:268–275Google Scholar
  9. 9.
    Bonavina L, Nosadini A, Bardini R, Baessato M, Peracchia A (1992) Primary treatment of esophageal achalasia. Long-term results of myotomy and Dor fundoplication. Arch Surg 127:222–226PubMedGoogle Scholar
  10. 10.
    Patti MG, Fisichella PM, Perretta S, Galvani C, Gorodner MV, Robinson T, Way LW (2003) Impact of minimally invasive surgery on the treatment of esophageal achalasia: a decade of change. J Am Coll Surg 196:698–703PubMedCrossRefGoogle Scholar
  11. 11.
    Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I (1996) Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 221:8–13PubMedGoogle Scholar
  12. 12.
    Dimenas E (1993) Methological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scan J Gastroenterol Suppl 199:18–21Google Scholar
  13. 13.
    Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27(Suppl):217–232CrossRefGoogle Scholar
  14. 14.
    Dupuy HJ (1984) The Psychological General Well-Being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CF (eds) Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. LeJacq Publishing Inc., New York, pp 170–183Google Scholar
  15. 15.
    Svedlund J, Sjödin I, Dotevall G (1988) GSRS: a clinical rating scale for gastrointestinal symtoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33:129–134PubMedCrossRefGoogle Scholar
  16. 16.
    Svedlund J, Sullivan M, Sjodin I, Liedman B, Lundell L (1996) Quality of life in gastric cancer prior to gastrectomy. Qual Life Res 5:255–264PubMedCrossRefGoogle Scholar
  17. 17.
    Korolija D, Sauerland S, Wood-Dauphinee S, Abbou CC, Eypasch E, Gareia Caballero M, Lumsden MA, Millat B, Monson JRT, Nilsson G, Pointer R, Schwenk W, Shamiyeh A, Szold A, Targarona E, Ure B, Neugebauer E (2004) Surg Endosc 18:879–897Google Scholar
  18. 18.
    Parkman HP, Reynolds JC, Ouyang A, Rosato EF, Eisenberg JM, Cohen S (1993) Pneumatic dilatation or esophagomyotomy treatment for idiopathic achalasia: clinical outcomes and cost analysis. Dig Dis Sci 38:75–85PubMedCrossRefGoogle Scholar
  19. 19.
    O’Connor JB, Singer ME, Imperiale TF, Vaezi MF, Richter JE (2002) The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci 47:1516–1525PubMedCrossRefGoogle Scholar
  20. 20.
    Imperiale TF, O’Connor JB, Vaezi MF, Richter JE (2000) A cost-minimization analysis of alternative treatment strategies for achalasia. Am J Gastroenterol 95:2737–2745PubMedCrossRefGoogle Scholar
  21. 21.
    Draaisma WA, Buskens E, Bais JE, Simmermacher RK, Rijnhart-de Jong HG, Broeders IA, Gooszen HG (2006) Randomized clinical trial and follow-up study of cost-effectiveness of laparoscopic versus conventional Nissen fundoplication. Br J Surg 93:690–697PubMedCrossRefGoogle Scholar
  22. 22.
    Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, Julkunen R, Levander K, Lamm M, Mattson C, Carlsson J, Stahlhammar NO (2001) The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 49:488–494PubMedCrossRefGoogle Scholar
  23. 23.
    van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309–319PubMedCrossRefGoogle Scholar
  24. 24.
    Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716–721PubMedCrossRefGoogle Scholar
  25. 25.
    Brauer CA, Rosen AB, Greenberg D, Neumann PJ (2006) Trends in the measurement of health utilities in published cost-utility analyses. Value Health 4:213–218CrossRefGoogle Scholar
  26. 26.
    Richards KF, Fisher KS, Flores JH, Christensen BJ (1996) Laparoscopic Nissen fundoplication: cost, morbidity, and outcome compared with open surgery. Surg Laparosc Endosc 6:140–143PubMedCrossRefGoogle Scholar
  27. 27.
    Romagnuolo J, Meier MA, Sadowski DC (2002) Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model. Ann Surg 236:191–202PubMedCrossRefGoogle Scholar
  28. 28.
    Van Den Boom G, Go PM, Hameeteman W, Dallemagne B, Ament AJ (1996) Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Scand J Gastroenterol 31:1–9Google Scholar
  29. 29.
    Csendes A, Braghetto I, Burdiles P, Korn O, Csendes P, Henriquez A (2006) Very late results of esophagomyotomy for patients with achalasia. Ann Surg 243:196–203PubMedCrossRefGoogle Scholar
  30. 30.
    Csendes A, Braghetto I, Henriquez A, Cortes C (1989) Late results of a prospective randomised study comparing forceful dilatation and esophagomyotomy in patients with achalasia of the esophagus. Gut 30:299–300PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • S. Kostic
    • 1
  • E. Johnsson
    • 2
  • A. Kjellin
    • 3
  • M. Ruth
    • 2
  • H. Lönroth
    • 2
  • M. Andersson
    • 4
  • L. Lundell
    • 3
  1. 1.Department of General SurgeryBorås Central HospitalBoråsSweden
  2. 2.Department of SurgerySahlgrenska University HospitalGothenburgSweden
  3. 3.Department of SurgeryKarolinska University HospitalStockholmSweden
  4. 4.Department of RadiologySahlgrenska University HospitalGothenburgSweden

Personalised recommendations